Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00437216
Status:
COMPLETED
Last Update Posted:
2022-07-29
First Post:
2007-02-16
Brief Title:
Efficacy Tolerance and Satisfaction With CLOBEX Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
Sponsor:
Galderma RD
Organization:
Galderma RD
Study Overview
Official Title:
Phase 4 Open-Label Multicenter Community-based 4-Wk Trial to Assess Efficacy Tolerance to Tx Patient Satisfaction w CLOBEX Spray When Used as Mono- or Add-on Therapy to Existing SystemicTopical Agents for Tx of Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of the effectiveness of Clobex Spray 005 when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents
Detailed Description:
Evaluation of the effectiveness of Clobex Spray 005 when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents as determined by the change in the target plaque severity TPS rating between Weeks 0 and 4
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None